Iron Triangle Partners LP Sells 16,455 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Iron Triangle Partners LP lessened its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 3.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 510,000 shares of the company’s stock after selling 16,455 shares during the quarter. Twist Bioscience accounts for approximately 3.2% of Iron Triangle Partners LP’s portfolio, making the stock its 15th largest position. Iron Triangle Partners LP owned about 0.87% of Twist Bioscience worth $23,042,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Principal Financial Group Inc. increased its position in shares of Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock valued at $6,057,000 after acquiring an additional 83,287 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Twist Bioscience by 215.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after purchasing an additional 20,035 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Twist Bioscience by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock worth $1,103,000 after buying an additional 2,292 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in shares of Twist Bioscience during the 2nd quarter valued at about $402,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Twist Bioscience in the 3rd quarter worth approximately $599,000.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of analyst reports. Evercore ISI increased their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Scotiabank upped their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Barclays decreased their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Finally, TD Cowen restated a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and an average target price of $51.00.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,730 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the sale, the chief executive officer now owns 495,523 shares in the company, valued at approximately $23,259,849.62. This trade represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now owns 45,620 shares of the company’s stock, valued at $2,034,652. The trade was a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 98,118 shares of company stock valued at $4,391,151 over the last 90 days. 3.92% of the stock is currently owned by corporate insiders.

Twist Bioscience Stock Up 2.3 %

TWST stock opened at $50.30 on Tuesday. The business’s 50-day moving average price is $43.94 and its 200-day moving average price is $46.24. Twist Bioscience Co. has a twelve month low of $24.15 and a twelve month high of $60.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.